摘要
目的:通过检测血清NTx、BSP水平预测唑来膦酸(Zoledronic Acid)治疗肺癌骨转移的临床疗效。方法:将64例确诊为非小细胞肺癌骨转移患者使用唑来膦酸治疗。用ELISA法测定患者治疗前后血清NTx和BSP浓度。结果:使用唑来膦酸治疗后骨转移瘤好转的患者血清NTx和BSP水平显著降低(P<0.01);骨转移无好转者血清NTx和BSP水平变化无显著差异(P>0.05)。结论:血清NTx、BSP的降低可以预测唑来膦酸能有效控制非小细胞肺癌骨转移,反之,无应用唑来膦酸的价值。
Objective：To study the clinical significance of Zoledronic Acid by examining serum pyridinoline cross-linked N-telopep tides of type Ⅰ collagen（NTx） and serum bone sialop rotein（BSP） in diagnosing bone metastasis of lung cancer.Methods：A total of 64 patients diagnosed with non-small cell lung cancer patients with bone metastasis treated with Zoledronic Acid.The levels of serum NTx and serum BSP were measured by EL ⅠSA.Results： The levels of serum NTx and BSP in patients with bone metastases were significantly lower after treatment of zoledronic acid（P0.01）;the levels of serum NTx and BSP in patients withoat bone metastases were no significant difference（P 0.05）.Conclusion：The reduction of serum NTx,BSP can predict that zoledronic acid can effectively control non-small cell lung cancer bone metastases.
出处
《现代肿瘤医学》
CAS
2011年第3期470-472,共3页
Journal of Modern Oncology
